Elo Mutual Pension Insurance Co Sells 5,334 Shares of Boston Scientific Co. (NYSE:BSX)

Elo Mutual Pension Insurance Co decreased its position in shares of Boston Scientific Co. (NYSE:BSX) by 3.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 134,390 shares of the medical equipment provider’s stock after selling 5,334 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Boston Scientific were worth $12,004,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Boston Scientific by 9.8% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,335,854 shares of the medical equipment provider’s stock valued at $211,839,000 after buying an additional 207,907 shares during the period. Penobscot Investment Management Company Inc. lifted its stake in shares of Boston Scientific by 70.5% in the 4th quarter. Penobscot Investment Management Company Inc. now owns 28,355 shares of the medical equipment provider’s stock valued at $2,533,000 after purchasing an additional 11,725 shares during the period. Morey & Quinn Wealth Partners LLC acquired a new position in shares of Boston Scientific in the 4th quarter valued at about $1,133,000. Mitsubishi UFJ Trust & Banking Corp boosted its position in shares of Boston Scientific by 1.3% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 843,293 shares of the medical equipment provider’s stock valued at $75,323,000 after purchasing an additional 11,214 shares in the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. grew its stake in Boston Scientific by 20.1% during the fourth quarter. Meiji Yasuda Asset Management Co Ltd. now owns 96,555 shares of the medical equipment provider’s stock worth $8,624,000 after purchasing an additional 16,184 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on BSX. Wells Fargo & Company increased their price target on Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Canaccord Genuity Group increased their target price on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Truist Financial lifted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. increased their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Finally, Barclays boosted their target price on Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Two analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $108.91.

Boston Scientific Stock Down 0.7 %

BSX stock opened at $102.31 on Thursday. Boston Scientific Co. has a 1-year low of $66.80 and a 1-year high of $107.17. The stock has a market cap of $151.32 billion, a P/E ratio of 81.85, a P/E/G ratio of 2.79 and a beta of 0.77. The stock’s fifty day simple moving average is $102.10 and its two-hundred day simple moving average is $92.87. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Analysts expect that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Activity

In other news, CFO Daniel J. Brennan sold 67,333 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the completion of the transaction, the chief financial officer now owns 225,808 shares in the company, valued at approximately $23,764,033.92. This represents a 22.97 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 1,201 shares of Boston Scientific stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the sale, the executive vice president now directly owns 25,443 shares of the company’s stock, valued at approximately $2,704,845.33. This trade represents a 4.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 137,302 shares of company stock valued at $14,319,269 in the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.